FDA Press Announcements · August 27, 2026 · Primary source
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
Summary
FDA approved Lisraya (brepocitinib) tablets on August 27, 2026, as the first oral drug indicated specifically for the treatment of dermatomyositis in adults. The approval addresses a long-standing unmet need in an inflammatory muscle disease for which prior treatments were borrowed from other disease indications. The press release quotes the Director of the Office responsible for the approval within FDA's drug review structure.
What this may mean
The approval creates a new reimbursement and formulary-placement question for health plans and Medicare Part B/D administrators covering dermatomyositis patients. Providers treating this condition now have an FDA-approved oral option to document in the medical record rather than relying on off-label therapies, which affects prior-authorization coding and coverage-determination workflows.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- FDA Press Announcements · October 5, 2026FDA Seeks Public Input to Support Ibogaine ResearchScore 58
- FDA Press Announcements · October 24, 2026FDA Issues Final Guidance on Prescription Drug Apps and SoftwareScore 46
- FDA Press Announcements · September 22, 2026FDA Updates Regulations to Advance Innovative Alternatives to Animal TestingScore 40
- FDA Press Announcements · September 4, 2026September 4, 2026 - FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition ProductsScore 40
- FDA Press Announcements · August 28, 2026August 28, 2026 - FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood DisorderScore 33
- FDA Press Announcements · September 4, 2026September 4, 2026 - FDA Grants Accelerated Approval to a New Breast Cancer TreatmentScore 32